Introduction
============

Triple-negative breast cancer (TNBC) (in which estrogen receptor, progesterone receptor, and HER2 are not overexpressed) is characterized by distinct clinical and pathologic features, metastatic behavior, a high recurrence rate, and poor prognosis compared with other breast cancer types [@B1]-[@B3]. TNBC does not respond to receptor-targeted treatments such as hormonal therapy and trastuzumab, leaving chemotherapy as the mainstay of treatment. It is now increasingly appreciated that combinatorial therapies are an essential path to achieving reliable treatment efficacy in TNBC. To facilitate such a multipronged approach, we need to find drugs that work together to modulate/target multiple hallmarks of cancer cell behavior.

Two-dimensional (2D) high-throughput kinome RNA interference (RNAi) screening has become a useful method for exploring the cellular signaling pathways that underlie cancer cell biology and for identifying target molecules for treatment [@B4]. Despite the powerful strategy of 2D high-throughput kinome RNAi screening in biological studies [@B5], [@B6], 2D monolayer cell growth model lacks the key component of cancer - the tumor microenvironment that can be tested *in vivo*[@B7], [@B8]. Three-dimensional (3D) cell cultures exhibit a higher degree of structural complexity and homeostasis, analogous to tissues and organs [@B9], and are currently used in a broad range of cell biology studies, including tumor biology studies [@B10]. Thus, we hypothesized that comprehensive RNAi analysis with 2D viability and 3D morphological assays would identify targets with better significance that can be a representative of clinical target for TNBC treatment. To test this hypothesis, we studied the role of gene knockdown under both 2D and 3D culture conditions to synergistically modulate the cancer growth phenotype in conjunction with a MEK inhibitor (AS703026). MDA-MB-231 cells were grown as either a 3D multicellular tumor spheroid (MCTS) cell culture system or as a 2D monolayer cell culture system. MDA-MB-231 cells demonstrate a unique 3D morphology comprising projections suggestive of epithelial-mesenchymal transition (EMT)-mediated invasion processes that are related to the cell line\'s spontaneous metastasis capability [@B11], [@B12].

The objective of this screen was to identify targets whose silencing by siRNA sensitized the TNBC cells to the MEK inhibitor, enhancing cell killing. Rather than focusing solely on a viability assay in 2D culture, we carried out a parallel screen utilizing a 3D culture that more closely resembled the *in vivo* environment to identify modulators of morphological formation of projections/filopodia. We identified and validated the PI3K pathway as a therapeutic target for combination with MEK inhibitor AS703026, a treatment strategy that is being assessed in phase I clinical trial expansion cohorts for TNBC patients.

Results
=======

Primary Screen
--------------

We first analyzed 760 kinases targeted by the human siRNA kinase library to identify gene profiles for the 2D monolayer cell culture and the 3D MCTS culture (Figure [1](#F1){ref-type="fig"}). In both types of culture, we identified genes that sensitized the cells to the MEK inhibitor, inducing greater than 50% cell growth inhibition or killing compared to cells treated with the solvent/vehicle.

Classification Results
----------------------

The confusion matrix for the no- vs long-projection phenotype classifier is shown in Table [1](#T1){ref-type="table"}. The entries in each cell represent the percentage of instances that were predicted by the computer model (divided into columns for each phenotype) and the actual instances (shown by rows). Table [2](#T2){ref-type="table"} shows the contingency table based on examining the intersection between the 2D and 3D screen outputs. We found that 5.1% of the genes conferred a growth inhibition phenotype in 2D culture and the "no-projection" phenotype in 3D culture. The panels of genes whose silencing induced this sensitization varied significantly between the 2D and 3D cell systems. The 3D model was superior as it enabled us to identify a panel of genes that had an effect on invasion as well as viability (Table [3](#T3){ref-type="table"}).

Ingenuity Pathway Analysis
--------------------------

We next analyzed the 5.1% of genes that led to no projections in the 3D MCTS system and were growth inhibition in the 2D monolayer system. The top five pathways that were over-represented based on these genes are listed in Table [4](#T4){ref-type="table"}. Based on these five top-ranked pathways, we used the "Overlay" feature in IPA to identify various drugs that could perturb the activity of these molecules. Further, we perturbed these molecules using the MAP feature in IPA (Figure [S1](#SM1){ref-type="supplementary-material"}). To identify genes that synergize with the MEK inhibitor\'s action and drive reduction in tumor growth morphology and viability, we used the MAP and upstream drug activity analysis functionality in IPA.[@B13] Examination of the top-ranking pathways in this set of genes revealed that the PI3K gene is present and the upstream of PI3K gene across the five pathways were related (Figure [3](#F3){ref-type="fig"}, Figure [S1](#SM1){ref-type="supplementary-material"}). Based on these observations, we hypothesized that a PI3K inhibitor would synergistically reduce tumor growth in conjunction with MEK inhibitor AS703026.

Drug-Combination Effect in TNBC Cell Lines
------------------------------------------

To validate whether inhibition of the PI3K and MEK pathways has a synergistic anti-proliferation effect in TNBC, we tested 6 different subtypes of TNBC cell lines (BL1, BL2, IM, MSL, M, and LAR), plus an unclassified (UC) cell line, as defined in previous studies [@B14], [@B15]. We evaluated the anti-proliferation index of combination treatment using an ATP-based cell viability assay, CellTiter-Blue reagent. When cells were treated with the combination of SAR245409 and AS703026 for 72 h, all tested cell lines showed IC50 values in the 0.3 - 3.0 μM range. In particular, we observed a significant shift in the IC50 value of both SAR245409 and AS703026 concentration in some BL2- and MSL-subtype cell lines (Table [5](#T5){ref-type="table"}, Figure [S2](#SM1){ref-type="supplementary-material"}). We next used the CalcuSyn program to analyze the fraction of cells affected by combination treatment with a clinically relevant dose (0.5 - 2.0 μM). Combinational index (CI) and fractional index (Fa) results suggested that SAR245409 and AS703026 enhanced the anti-growth effect in TNBC cell lines, specifically in the BL2 and MSL subtypes (Table [6](#T6){ref-type="table"}).

Next, to discover whether the combination of SAR245409 and AS703026 enhances the anti-tumorigenic effect in TNBC cells, we performed *in vitro* tumorigenicity assays using soft-agar colony formation. We observed that when cells were treated with IC50 concentrations (1 µM) of SAR245409 and AS703026, more than 90% of cells did not form colonies (Figure [S3](#SM1){ref-type="supplementary-material"}). Thus, at these concentrations, it was difficult to evaluate the synergistic anti-tumor effect of combination treatment. Therefore, we selected doses that were one-tenth or one-hundredth lower than the initial concentrations (0.1 µM or 0.01 µM) for treatment. As shown in Figure [4](#F4){ref-type="fig"}, colony numbers were significantly lower with combination treatment than with single treatment in most tested TNBC cell lines except BT-20 cell line.

Our Ingenuity pathway analysis revealed that p21-activated kinase (PAK) group II, PAK4 and PAK6, and Rho GTPase RAC1 were the most common genes from the 3D siRNA screening assays. Previous studies indicated that PAK4 and RAC1 are key regulators of not only migration/invasion but also tumorigenicity in breast cancer [@B16]-[@B20]. Therefore, we further tested whether the combination of SAR245409 and AS703026 inhibits TNBC cell migration and invasion. As shown in Figures [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B, compared with single treatment, combination treatment with SAR245409 and AS703026 (0.5 µM) inhibited both migration and invasion significantly in both TNBC cell lines tested (*p*\<0.001). PAK and RAC1 have been described as regulatory factors in cellular morphological formation of lamellipodia, membrane ruffling, and filopodia and stress fibers during migration or invasion [@B21]. We observed that control or single-treatment cells showed well-developed lamellipodia or filopodia, as indicated by the arrows in Figures [5](#F5){ref-type="fig"}C and [5](#F5){ref-type="fig"}D; however, combination treatment cells had restricted lamellipodium and filopodium development. These data indicated that combination treatment of SAR245409 and AS703026 inhibited migration/invasion by inhibiting the small GTPase signaling pathway. Also, the conventional assay method successfully reproduced the 3D RNAi screening result.

Discussion
==========

In the present study, we used high-throughput 2D and 3D RNAi screening to identify targets whose silencing induced growth inhibition or projection formation of TNBC cells treated with AS703026. Our comprehensive analysis revealed the PI3K pathway as an important target in TNBC cell growth and migration/invasion under AS703026 treatment. We validated that compared with single-agent treatment, the combination of AS703026 and PI3K inhibitor SAR245409 enhanced TNBC cell growth inhibition as well as inhibition of migration and invasion ability. These data indicate that combination of AS703026 and SAR245409 could be a candidate strategy for inhibiting TNBC cell growth and metastasis.

It has been demonstrated by many studies that 2D monolayer cancer cell culture is a somewhat artificial model and does not fully represent the characteristics of 3D solid tumors [@B22]. Our group also observed that gene profiling did not perfectly match between TNBC cell line microarray and TNBC patient microarray data using Lehmann and Bauer\'s analysis algorithm [@B14], [@B15]. Li et al reported that most anticancer drugs and molecular targeted therapies have shown promise in preclinical studies; however, cancer patients have shown a much lower response rate to the drugs compared to *in vitro* chemosensitivity [@B23]. This low response rate to anti-cancer drugs has been attributed to the tumor microenvironment [@B24]. The 3D MCTSs are of intermediate complexity between *in vivo* tumors and monolayer cultures, and their growth emulates the heterogeneity of solid tumors; necrosis and radiation-resistant hypoxic regions often occur at the center of solid tumors due to poor vasculature and subsequent lack of oxygen supply [@B25]. Our unique multicellular spheroid models are an effective 3D cell culture model that takes advantage of the natural tendency of cells to aggregate*.*

The ability of multicellular spheroids to simulate a tumor-like environment, together with the ease by which these models can be applied in high-throughput screens [@B26], [@B27], has resulted in the use of spheroids to study drug efficacy and penetration as well as 3D cellular interactions [@B25], [@B28]-[@B36]. For example, several *in vitro* lines of evidence indicate that the ribosomal S6 kinase (RSK) family promotes head and neck squamous cell carcinoma cell metastasis [@B37], breast epithelial cell motility [@B38], and cell adhesion [@B39]. Since RSKs are activated by the MAPK pathway [@B40] and large proportion of breast cancer cells show elevated EGFR-MAPK pathway activity [@B41], RSKs are recognized as a target for inhibiting migration and invasion processing in breast cancer. In contrast to expectations, 2D/3D RNAi screening revealed that the RSK gene is not correlated with TNBC cell projection formation, meaning there was no effect on the cells\' migration. We confirmed this result using pan-RSK inhibitor (BI-D1870) with two TNBC cell lines; we did not observe an inhibition effect on migration and invasion ability with this RSK inhibitor (Figure [S4](#SM1){ref-type="supplementary-material"}). This result indicates that our comprehensive RNAi screening and morphological analysis is able to identify target molecules that might effectively prevent cell growth and migration/invasion in an *in vivo* setting.

Compared to other breast cancer types, TNBCs have more aggressive behavior that tends to metastasize and survive, resulting in a high distant-recurrence rate [@B42], [@B43]. Among the 6 different subtypes of TNBC, the MSL subtype displays unique ontologies related to cell motility, extracellular matrix interaction, inositol phosphate metabolism, EGFR, and ERK1/2 signaling [@B14]. Owing to prominent EMT and stem cell-like properties, the MSL subtype showed decreased distant-metastasis-free survival compared to other TNBC subtypes [@B15]. Several articles have also reported that elevated tyrosine kinase receptor, activated PI3K/AKT/mTOR and MAPK/ERK pathways, and mutated PIK3CA are frequently observed in TNBC, specifically in metaplastic breast cancers [@B44]-[@B46]. Of note, the MSL-subtype MDA-MB-231 cells used in the 2D/3D RNAi screening displayed target genes closely related to ErbB and the migration/invasion pathway. We identified PI3K and PAK4/6 pathways as top candidates for combination with AS703026. Current evidence indicates that the PAK4/6 pathway is activated via either the PI3K/AKT or the MAPK/ERK pathway and enhances processes associated with progression of cancer such as proliferation, survival, metastasis, and EMT [@B47]-[@B50]. In the process of EMT, including migration/invasion, PAKs regulate cell polarization, resulting in formation of pseudopodia and membrane ruffles [@B51]. PAK4 is highly overexpressed in metastatic breast cancer cell lines [@B52], [@B53], and our data showed strong inhibition of pseudopodia and membrane ruffles by the AS703026 and SAR245409 combination. These findings suggest that metastatic TNBC with a high PAK4 level may be well suited to a new targeted therapy opportunity with a MEK inhibitor and PI3K inhibitor. Further investigation is needed to translate our result into *in vivo* conditions to determine whether the combination of AS703026 and SAR245409 can suppress tumor growth and metastasis effectively. Such data would provide strong justification for future clinical trials to target metastatic TNBC.

In summary, our results suggest that integrated and multi-system RNAi screening methods and analysis narrow the inherent difference between *in vitro* and *in vivo* conditions, providing powerful high-throughput assays that are able to identify anticancer drugs as single or combinational agents. In testing these methods, we have demonstrated that combining AS703026 and SAR245409 effectively suppressed proliferation and colony formation as well as migration/invasion of TNBC cells. We look forward to advancing the field of therapeutic development with AS703026 and SAR245409 for patients with metastatic TNBC.

Materials and Methods
=====================

Therapeutic Agents and Cell Lines
---------------------------------

AS703026 and SAR245409 were provided by EMD Serono Research & Development Institute, Inc. and Sanofi Inc., respectively. Human breast cancer cell lines MDA-MB-231, HCC1937, MDA-MB-468, HCC1187, HCC70, BT-549, Hs578T, MDA-MB-157, MDA-MB-436, MDA-MB-231, MDA-MB-453, and BT-20 were purchased from ATCC. Human breast cancer cell lines SUM149 and SUM159 were purchased from Asterand. We authenticated all of the cell lines by genotyping through MD Anderson Cancer Center\'s Characterized Cell Line Core Facility.

High-Throughput siRNA Screening
-------------------------------

High-throughput RNAi screens for target identification and synthetic lethality were performed following stringent standard operating procedures at the RNAi screening facility at MD Anderson Cancer Center.[@B54]-[@B57] MDA-MB-231 cells were grown as either a 3D multicellular tumor spheroid (MCTS) cell culture system or as a 2D monolayer cell culture system. MDA-MB-231 cells demonstrate a unique 3D morphology comprising projections suggestive of epithelial-mesenchymal transition (EMT)-mediated invasion processes that are related to the cell line\'s spontaneous metastasis capability [@B11], [@B12]. Both a 2D monolayer culture and a 3D MCTS culture of MDA-MB-231 cells were transfected, utilizing the reverse transfection procedure with an siGENOME SMARTpool kinome siRNA library comprising a pool of 4 individual siRNA duplexes targeting the individual kinases (Dharmacon). The 3D MCTS were generated by growing the cells on non-matrix transparent cycloolefin resinous sheets comprising nanoscale indented patterns with a 500-nm line width, 1-mm line depth, and 10-mm to 500-nm line spacing [@B58]. The screen performed in the 2D system was designed to identify genes that affect tumor viability, while the screen performed in the 3D system was designed to identify genes that affect tumor viability as well as modulate the outgrowth of cellular projections, which reflect cell motility and invasive capability. Briefly, for the screen performed utilizing the 2D monolayer cell culture, 10 μl of 200 nM siRNA was mixed with 10 μl of a lipid (0.07 μl of DharmaFECT 1 reagent in 10 μl Opti-MEM medium) for 20 min in a well of a 384-well plate (Corning) and overlaid with 30 μl of cell suspension (5,000 cells) in antibiotic-free cell line-specific media. The final concentration of siRNA in both models was 40 nM per well. siControl ON-TARGETplus siRNA number 4 (siOTP4, Dharmacon) and siTOX ON-TARGETplus (Dharmacon) were used as the negative and positive transfection controls, respectively, in all experiments. In the case of the 3D spheroids, 20 μl of 200 nM siRNA was mixed with 20 μl of a lipid (0.24 μl of DharmaFECT 1 reagent in 20 μl Opti-MEM medium) (Invitrogen) for 20 min in a well of a 96-well NanoCulture plate (SCIVAX Inc.) and overlaid with 60 μl of cell suspension (10,000 cells) in antibiotic-free cell line-specific media. The screen using the 2D monolayer cell culture was performed in triplicate, while the screen using the 3D spheroid cell culture was performed in duplicate. Forty-eight hours after transfection, MEK inhibitor AS703026 was added at a final concentration of 75 nM (the IC20 value) to one set of transfected plates, and a similar volume of DMSO (\> 0.1%) was added to the other set of transfected plates. After 72 h of incubation, the cells growing in 3D spheroids were imaged using an In Cell Analyzer 1000 (GE). All images were analyzed for morphological changes following the creation of study-specific programs utilizing GE In Cell Investigator software. The viability of the cells growing in the 2D monolayer or 3D spheroid cultures was determined using the CellTiter-Glo luminescent cell viability assay (Promega) according to the manufacturer\'s instructions.

Classification of 3D siRNA Culture Outcome
------------------------------------------

To analyze 3D siRNA screening result, we followed below four classification steps (summarized in Figure [2](#F2){ref-type="fig"}).

### Step 1: imaging analysis and data extraction

Since the task of manually annotating the cells into different phenotypic groups is laborious and time consuming, we examined a machine-learning approach to solve this issue: the image-derived features were used to develop a statistical classifier that can predict an expert-annotated class label. A difference in projection type can be used for imaging classifying system. Field-level images were processed using GE IN Cell Investigator software. Briefly, images were pre-processed to adjust contrast and remove artifacts. Subsequently, segmentation routines were used to segment blobs of cells, followed by measurement of morphological parameters such as area, form factor, perimeter, and diameter. The final data output from the analysis tool was a matrix in which each row represents each field within a well, and the columns represented the various morphological features (area, perimeter, diameter, form factor). A board-certified breast medical oncologist (NTU) annotated a subset of images as "long projection", "no projection", and "dead" phenotypes. Based on this annotation, a classification model was built that can discriminate long-projection and no-projection phenotypes. Using the GE IN Cell Analyzer tool, we measured "cell bodies", representing entities after segmentation, and "cell clumps", representing entities before segmentation. These morphological features were computed for each field in the well through the following nine measurements: 1) total area of cell bodies, 2) mean area of cell bodies, 3) number of cell bodies, 4) mean form factor of cell bodies, 5) mean diameter of cell bodies, 6) mean perimeter of cell bodies, 7) mean % area of image occupied by all cell clumps, 8) total area of cell clumps, and 9) mean area of connected cell clumps (% of all cell clumps).

### Step 2: data mining

To automatically score cells based on \'projection\' based phenotypes, we used a random forest classifier. A "random forest" is an ensemble of classifiers obtained by aggregating (bagging) several classification trees. Each data point (represented as an input vector) is classified based on the majority vote gained by that vector across all the "trees" of the forest. Each tree of the forest is "grown" in the following way:A bootstrapped sample (with replacement) of the training data is used to grow each tree. The sampling for bootstrapped data selection is done individually at each tree of the forest.For an M-dimensional input vector, a random subspace of m (≪ M) dimensions is selected, and the best split on this subspace is used to split the node. This is done for all nodes of the tree.

Before sampling for aggregating process, one-third of the cases are kept "out of the training bag." These out-of-bag (OOB) data are used to obtain an unbiased estimate of the classification error as trees are added to the forest. They are also used to get estimates of variable importance. Several interesting insights into the data are available using random forest analysis. The variable importance plot yields the variables that are most discriminatory for classification under the "ensemble of trees" classifier. This importance is based on two measures: Gini index and decrease in accuracy. The Gini index is an entropy-based criterion that measures the purity of a node in the tree, while the decrease in accuracy simply looks at the relative contribution of each variable to the accuracy of the classifier. For our studies, we used the randomForest package for R. The classifier performance on the individual data was assessed via a confusion matrix.

### Step 3: contingency table

Further, a contingency table for the genes was built in the following manner:For the 2D setting, we examined the viability of TNBC cells with gene knockdown; we compared cells treated with AS703026 vs. untreated cells. Genes that led to a reduction in viability less than vehicle control were designated "growth inhibition", whereas the rest were designated "no growth inhibition".For the 3D setting, using the no-projection vs. long-projection classifier, each gene was designated as a "no-projection" gene if its knockdown led to loss of the projection phenotype. Otherwise, it was designated as a "long-projection" gene.

Using definitions from (i) and (ii) above, we populated a contingency table across the 2D (viability) and 3D (no-projection phenotype) settings.

### Step 4: Functional Analysis of Genes

Network and functional analysis of the genes inducing the no-projection phenotype was carried out using the Ingenuity Pathway Analysis tool. The tool provides output comprising the top-ranking pathways involving these genes (based on a Fisher exact test). We explored both "Direct and Indirect Interactions" using "Experimentally Verified Predictions" in the Ingenuity Knowledge Base (Genes and Endogenous Chemicals).

Ingenuity Pathway Analysis (IPA)
--------------------------------

IPA was used to derive functional and pathway information from the list of genes ("hits") associated with the growth inhibition and no-projection phenotypes. Further, IPA was also used for network analysis of drug-induced perturbation of pathway activity. More details are in the Supplementary Information. To identify targetable genes that synergize with MEK inhibitor action to drive reduction in tumor growth morphology and viability, we used the Molecule Activity Predictor (MAP) and upstream drug activity analysis functionality in IPA [@B13]. Briefly, based on the top-ranked pathways corresponding to the gene hits, we used the "Overlay" feature in IPA to overlay various drugs that could perturb the activity of these molecules. Further, we perturbed these molecules using the MAP feature in IPA.

*In Vitro*Cell Proliferation Assay and Analysis of Combinational Drug Effect
----------------------------------------------------------------------------

Cells were treated with the drug combination and analyzed using a CellTiter-Blue assay (Promega) according to the manufacturer\'s instructions. Drug synergy was determined by the isobologram and combination-index methods using CalcuSyn software 2.1 (Biosoft) [@B59]. Detailed methods are described in the Supplementary Information.

Anchorage independent colony formation assay (Soft Agar Assay)
--------------------------------------------------------------

TNBC cells (2×10^3^ cells/well) were resuspended in 2 ml of 0.4% agarose solution in DMEM/F12 or F12 medium (Sigma) and overlaid onto the bottom agar layer (0.8%) in 6-well plates. The plates were incubated for 3 to 6 weeks with the two drugs, and colonies were stained with 200 μl of MTT solution (Sigma, 1 mg/ml) for 2 h. The number of stained colonies greater than 80 μm in diameter was counted using the GelCount colony-counting system (Oxford Optronix) according to the manufacturer\'s instructions. Means and standard deviations were calculated on the basis of the colony counts from triplicate wells.

Migration and Invasion Assay
----------------------------

Migration assays were performed in triplicate using a chemotaxis chamber (24-well inserts, 8-µm pore size, BD Biosciences). Cells were harvested and resuspended in DMEM/F12 media with 1 mg/ml bovine serum albumin (Sigma). 1×10^5^ cells/350 μl were plated on upper chambers, and bottom wells were filled with 750 μl of DMEM/F12 media that included 2% FBS and 100 ng/ml EGF (Invitrogen) as an attractant to induce migration or invasion. Six hours later, membranes were fixed and stained with Diff-Quik solutions (Dade Behring, Inc.). Chemotaxis was quantitated by the ImageJ program. For invasion, 50 µl of 10% Matrigel solution was coated on the upper chamber for 1 h at 37ºC. Cells were allowed to invade for 24 h.

Statistical Analysis
--------------------

For experimental outcomes, descriptive statistics (mean and standard deviation) were summarized for each group. An analysis of variance model was used to compare the mean outcome values among the tested groups. Statistical analyses were performed using an unpaired *t*-test with Prism version 5 (GraphPad Software). *P* values of \<0.05 were considered statistically significant.

Supplementary Material
======================

###### 

Figures S1-S4.

###### 

Click here for additional data file.
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![**High-throughput RNAi screen using a 3D multicellular tumor spheroid model of breast cancer.**(A) The breast cancer cell line MDA-MB-231 was grown on a non-matrix transparent cycloolefin resinous scaffold comprising nanoscale indented patterns with a 500-nm line width, 1-mm line depth, and 10-nm to 500-nm line spacing. Cells grown on this surface form 3D multicellular tumor spheroids with projections. (B) The high-throughput screen was performed in 96-well plates in duplicates. The readouts for the screen were morphology and viability. (C, D) Images from 3D culture plates. Ten images were captured per well for a total of 20 images for each siRNA.](jcav06p1306g003){#F1}

![**Image analysis procedure of 3D culture siRNA screening outcome.**Step 1: Imaging analysis and data extraction, ①; Step 2: Data mining, ②; Step 3: Contingency table, ③; Step 4: Functional analysis of genes, ④](jcav06p1306g004){#F2}

![**Ingenuity pathway analysis (IPA) revealed a key role for the Molecular Mechanisms of Cancer set of pathways.**We analyzed the subset of genes whose knockdown in TNBC cells treated with MEK inhibitor AS703026 led to no projections in the 3D MCTS system and were growth inhibition in the 2D monolayer system (5.1%). Molecular Mechanisms of Cancer was a top-ranking pathway. Output data indicated that PI3K pathway-related genes are the most important target molecules for combination with MEK inhibitor AS703026. Pink color indicated-gene: target gene from 2D/3D siRNA screening analysis. Blue color indicated-gene: negatively regulated downstream molecule by inhibition of pink color indicated-target molecule. Yellow color indicated-gene: possible mechanism on apoptosis by inhibition of target genes from 2D/3D siRNA screening. XL-147: a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ.](jcav06p1306g005){#F3}

![**The combination of AS703026 with SAR245409 significantly enhanced antitumor effect in anchorage independent colony formation assay (soft agar assay).** Breast cancer cell lines were overlaid onto the bottom agar layer (0.8%) with the indicated drugs (µM) and incubated for 3-6 weeks. For visualizing, colonies were stained with 200 μl of MTT (1 mg/ml) solution for 2 h and counted using the GelCount colony-counting system according to the manufacturer\'s instructions. Statistical significance was evaluated by *t*test using GraphPad Prism software. Error bars represent the standard deviation of three independent experiments. \*, *p* \<0.05 combination compared with SAR245409; ^†^, *p* \<0.01 combination compared with AS703026. BL1: basal-like 1, BL2: basal-like 2, MSL: mesenchymal stem-like, LAR: luminal androgen receptor, UC: unclassified.](jcav06p1306g006){#F4}

![**The combination of AS703026 and SAR245409 suppressed SUM149 and MDA-MB-231 cell migration and invasion capability**. (A, B) Migration and invasion assay results. *P* values are indicated between bars; statistical significance was evaluated by *t*test using GraphPad Prism software. Error bars represent the standard deviation of three independent experiments. (C, D) Images for SUM149 and MDA-MB-231 cells subjected to a migration assay with or without drugs for 6 h. Cells were fixed and stained with Diff-Quik solution. Arrows indicate filopodia or membrane ruffling formations.](jcav06p1306g007){#F5}

###### 

The confusion matrix representing the performance of the no- vs long-projection phenotype classifier for 3D culture results. rows represent the actual labels (based on human expert annotation) of the cells\' morphology, whereas columns represent the labels predicted by the random forest classifier. The accuracy of the classifier was 91%.
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###### 

Contingency table based on examining the intersection between 2D and 3D RNAi screening. The entries denote the number of genes that confer the indicated morphological designations under 2D and 3D culture conditions (eg: 48.9% of the genes conferred the "no growth inhibition" phenotype in 2D culture but the "long-projection" phenotype in 3D culture). The determination of 3D morphology was made based on decisions outputted by the morphology classifier shown in Table [1](#T1){ref-type="table"}.

![](jcav06p1306g002)

The entries in each cell indicate the number of genes that have the characteristics in the type of culture shown by the column and row headings.

###### 

Genes whose silencing led to a no-projection phenotype in the 3D screen, grouped by the outcome of the 2D siRNA screen.

  Gene symbol                                                                         Accession no.   Gene name
  ----------------------------------------------------------------------------------- --------------- -----------------------------------------------------------------------------
  No growth inhibition outcome in 2D/ no projection in 3D culture (5.1 %, 39 genes)                   
  ADRBK2                                                                              NM_001619       adrenergic, beta, receptor kinase 1
  ANGPT4                                                                              NM_015985       angiopoietin 4
  ATR                                                                                 NM_001184       ataxia telangiectasia and Rad3 related
  CDKN3                                                                               NM_005192       cyclin-dependent kinase inhibitor 3
  CKMT1                                                                               NM_020990       creatine kinase, mitochondrial 1B
  CKMT2                                                                               NM_001825       creatine kinase, mitochondrial 2
  CNKSR1                                                                              NM_006314       connector enhancer of kinase suppressor of Ras 1
  DUSP1                                                                               NM_004417       dual specificity phosphatase 1
  DUSP10                                                                              NM_007207       dual specificity phosphatase 10
  DYRK1B                                                                              NM_004714       dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B
  EPHA1                                                                               NM_005232       EPH receptor A1
  FLJ10761                                                                            NM_018208       Ethanolamine kinase 2 (ETNK2)
  FLJ34389                                                                            NM_152649       Mixed lineage kinase domain-like (MLKL), transcript variant 1
  FUK                                                                                 NM_145059       Fucokinase
  MERTK                                                                               NM_006343       c-mer proto-oncogene tyrosine kinase
  MGC4796                                                                             NM_032017       serine/threonine kinase 40 (STK40), transcript variant 3
  MGC5601                                                                             NM_025247       acyl-CoA dehydrogenase family, member 10 (ACAD10), transcript variant 2
  PAG                                                                                 NM_018440       phosphoprotein associated with glycosphingolipid microdomains 1
  PDK3                                                                                NM_005391       pyruvate dehydrogenase kinase, isozyme 3 (PDK3), transcript variant 2
  PDPK1                                                                               NM_002613       3-phosphoinositide dependent protein kinase-1 (PDPK1), transcript variant 1
  PFTK1                                                                               NM_012395       cyclin-dependent kinase 14 (CDK14)
  PIK3C2G                                                                             NM_004570       phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma
  PKN3                                                                                NM_013355       protein kinase N3
  PPP2CB                                                                              NM_004156       protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform
  PRKAA2                                                                              NM_006252       protein kinase, AMP-activated, alpha 2 catalytic subunit
  PAK4                                                                                NM_005884       p21 protein (Cdc42/Rac)-activated kinase 4
  PRKCN                                                                               NM_005813       protein kinase D3
  PRKCQ                                                                               NM_006257       protein kinase C, theta
  PRPSAP1                                                                             NM_002766       phosphoribosyl pyrophosphate synthetase-associated protein 1
  PTPRR                                                                               NM_002849       protein tyrosine phosphatase, receptor type, R
  SNRK                                                                                NM_017719       SNF related kinase
  SSTK                                                                                NM_032037       testis-specific serine kinase 6
  STK19                                                                               NM_004197       serine/threonine kinase 19
  STK31                                                                               NM_031414       serine/threonine kinase 31
  STK35                                                                               NM_080836       serine/threonine kinase 35
  STK36                                                                               NM_015690       serine/threonine kinase 36
  STYK1                                                                               NM_018423       serine/threonine/tyrosine kinase 1
  TEX14                                                                               NM_031272       testis expressed 14
  TNK1                                                                                NM_003985       tyrosine kinase, non-receptor, 1
  Growth inhibition outcome in 2D/ no projection in 3D culture (3.4 %, 26 genes)                      
  CDC42BPA                                                                            NM_003607       CDC42 binding protein kinase alpha
  CDK6                                                                                NM_001259       cyclin-dependent kinase 6
  CDKN1B                                                                              NM_004064       cyclin-dependent kinase inhibitor 1B
  MYO3A                                                                               NM_017433       myosin IIIA
  NTRK3                                                                               NM_002530       neurotrophic tyrosine kinase, receptor, type 3
  PAK6                                                                                NM_020168       p21 protein (Cdc42/Rac)-activated kinase 6
  PANK4                                                                               NM_018216       pantothenate kinase 4
  PAPSS1                                                                              NM_005443       3\'-phosphoadenosine 5\'-phosphosulfate synthase 1
  PCTK1                                                                               NM_006201       cyclin-dependent kinase 16
  PCTK3                                                                               NM_002596       cyclin-dependent kinase 18
  PFKP                                                                                NM_002627       phosphofructokinase, platelet
  PGK2                                                                                NM_138733       phosphoglycerate kinase 2
  PHKG2                                                                               NM_000294       phosphorylase kinase, gamma 2
  PIP5K1A                                                                             NM_003557       phosphatidylinositol-4-phosphate 5-kinase, type I, alpha
  PRKCE                                                                               NM_005400       protein kinase C, epsilon
  PRKD2                                                                               NM_016457       protein kinase D2
  PRKWNK4                                                                             NM_032387       WNK lysine deficient protein kinase 4
  PTK6                                                                                NM_005975       protein tyrosine kinase 6
  RAC1                                                                                NM_018890       ras-related C3 botulinum toxin substrate 1
  SGK2                                                                                NM_016276       serum/glucocorticoid regulated kinase 2
  SPEC2                                                                               NM_020240       CDC42 small effector 2
  SPHK1                                                                               NM_021972       sphingosine kinase 1
  SPHK2                                                                               NM_020126       sphingosine kinase 2
  STK25                                                                               NM_006374       serine/threonine kinase 25
  TPK1                                                                                NM_022445       thiamin pyrophosphokinase 1
  TXK                                                                                 NM_003328       TXK tyrosine kinase

###### 

IPA pathway analysis of the 5.1% of the genes in Table [2](#T2){ref-type="table"} that led to no projection in the 3D MCTS system and a growth inhibition outcome in the 2D monolayer system. The five top-ranked pathways corresponding to the gene hits are listed.

  Pathway name                     Genes common to the pathway and the list of hits from the 3D screen
  -------------------------------- --------------------------------------------------------------------------
  Erbb Signaling                   PAK4, PAK6, PDPK1, PIK3C2G, PRKCE, PRKCQ, PRKD3
  Molecular Mechanisms of Cancer   ATR, CDK6, CDKN1B, PAK4, PAK6, PIK3C2G, PRKCE, PRKCQ, PRKD3, RAC1, STK36
  Renin-Angiotensin Signaling      PAK4, PAK6, PI3KC2G, PRKCE, PRKCQ, PRKD3, RAC1
  NK Cell Signaling                PAK4, PAK6, PIK3C2G, PRKCE, PRKCQ, PRKD3, RAC1
  CCR3 Signaling in Eosinophils    PAK4, PAK6, PIK3C2G, PRKCE, PRKCQ, PRKD3, RAC1

###### 

IC50 values for single and combinational treatment with AS703026 and SAR245409 in TNBC cells under 2D culture conditions.

  Subtype                     TNBC cell line   Single treatment   Combinational treatment   
  --------------------------- ---------------- ------------------ ------------------------- ------
  Basal-like                  HCC1937 (BL1)    1.07               \> 20                     1
  MDA-MB-468 (BL1)            1.98             2.5                1.2                       
  HCC1187 (IM)                0.25             1.17               0.3                       
  HCC70 (BL2)                 0.37             12.7               0.38                      
  SUM149 (BL2)                1.7              0.95               0.32                      
  HCC1806 (BL2)               2.2              12.5               0.9                       
  Mesenchymal-like            HS578T (MSL)     0.5                4.84                      0.52
  MDA-MB-157 (MSL)            6.48             \> 20              2.76                      
  SUM159 (MSL)                7.3              \> 20              2.78                      
  MDA-MB-436 (MSL)            0.28             2.7                1                         
  MDA-MB-231 (MSL)            1.36             0.6                0.12                      
  BT-549 (M)                  0.56             \> 20              1.2                       
  Luminal androgen receptor   MDA-MB-453       0.18               6.32                      1.04
  Unclassified                BT-20            1.2                9                         0.58

Six different subtypes of TNBC were identified based on gene expression profiles: basal-like 1 and 2 (BL1 and BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR) [@B14].

###### 

Combinational index (CI), a quantitative measure of the degree of drug interaction, and fractional index (Fa), the fraction of cells affected by the treatment, for the drug combination AS703026 and SAR245409 (1:1 mix ratio).

  ----------------------------------------------------------------------------------------------------------------------------
  Cell line and TNBC subtype   CI/Fa values for different concentrations of the drugs\                                 
                               (1:1 mix ratio)                                                                         
  ---------------------------- --------------------------------------------------------- ------- ------ ------- ------ -------
  HCC1937 (BL1)                0.43                                                      0.174   0.45   0.813   0.59   0.724

  MDA-MB-468 (BL1)             0.4                                                       0.795   0.54   0.635   0.68   0.572

  HCC1187 (IM)                 0.72                                                      0.405   0.74   0.603   0.81   0.49

  HCC70 (BL2)                  0.75                                                      0.302   0.86   0.24    0.94   0.135

  SUM149 (BL2)                 0.78                                                      0.079   0.84   0.079   0.89   0.081

  HCC1806 (BL2)                0.51                                                      0.216   0.62   0.263   0.72   0.325

  HS578T (MSL)                 0.61                                                      0.517   0.75   0.459   0.87   0.341

  MDA-MB-157 (MSL)             0.23                                                      0.155   0.29   0.233   0.52   0.284

  SUM159 (MSL)                 0.32                                                      0.078   0.55   0.076   0.65   0.112

  MDA-MB-436 (MSL)             0.57                                                      0.91    0.84   0.659   0.91   0.595

  MDA-MB-231 (MSL)             0.88                                                      0.025   0.87   0.053   0.96   0.055

  BT-549 (M)                   0.51                                                      0.794   0.61   0.899   0.72   1

  MDA-MB-453 (LAR)             0.79                                                      0.44    0.85   0.498   0.92   0.402

  BT-20 (UN)\*                 0.51                                                      0.317   0.68   0.25    0.82   0.19
  ----------------------------------------------------------------------------------------------------------------------------

\*UN, unstable (those TNBCs that do not fall consistently into one of the six subtypes). CI value: \<0.1 indicates very strong synergism; 0.10-0.30, strong synergism; 0.31-0.70, synergism; 0.71-0.85, moderate synergism; 0.86-0.90, slight synergism; 0.91-1.10, nearly additive; 1.11-1.20, slight antagonism; 1.21-1.45, moderate antagonism; 1.46-3.30, antagonism; 3.31-10, strong antagonism; \>10, very strong antagonism.
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